Pamela A Mccombe

List of Publications by Year
in descending order

278	12,239	36691	37326
papers	citations	53 h-index	100 g-index

291	291	291	12701
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Polygenic risk score analysis for amyotrophic lateral sclerosis leveraging cognitive performance, educational attainment and schizophrenia. European Journal of Human Genetics, 2022, 30, 532-539.	1.4	16
2	NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand. Journal of Neurology, 2022, 269, 836-845.	1.8	5
3	Monocyte CD14 and HLA-DR expression increases with disease duration and severity in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 430-437.	1.1	4
4	Low plasma hyaluronan is associated with faster functional decline in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 42-48.	1.1	0
5	Prediction of multiple sclerosis outcomes when switching to ocrelizumab. Multiple Sclerosis Journal, 2022, 28, 958-969.	1.4	6
6	Biofluid of Amyotrophic Lateral. Neuromethods, 2022, , 263-306.	0.2	1
7	Functional characterisation of the amyotrophic lateral sclerosis risk locus GPX3/TNIP1. Genome Medicine, 2022, 14, 7.	3.6	12
8	Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Science Translational Medicine, 2022, 14, eabj0264.	5.8	38
9	Novel Variants of ANO5 in Two Patients With Limb Girdle Muscular Dystrophy: Case Report. Frontiers in Neurology, 2022, 13, 868655.	1.1	0
10	The role of sex and pregnancy in multiple sclerosis: what do we know and what should we do?. Expert Review of Neurotherapeutics, 2022, 22, 377-392.	1.4	2
11	Bi-allelic loss-of-function OBSCN variants predispose individuals to severe recurrent rhabdomyolysis. Brain, 2022, 145, 3985-3998.	3.7	6
12	Impaired signaling for neuromuscular synaptic maintenance is a feature of Motor Neuron Disease. Acta Neuropathologica Communications, 2022, 10, 61.	2.4	6
13	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology, 2022, , .	1.7	1
14	Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy. Multiple Sclerosis Journal, 2021, 27, 465-474.	1.4	23
15	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 755-766.	1.4	11
16	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. Multiple Sclerosis Journal, 2021, 27, 695-705.	1.4	7
17	Elevated plasma levels of D-serine in some patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 206-210.	1.1	7
18	Disorders of sleep and wakefulness in amyotrophic lateral sclerosis (ALS): a systematic review. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 161-169.	1.1	16

#	Article	IF	Citations
19	Clinical and electrophysiological examination of pinch strength in patients with amyotrophic lateral sclerosis. Muscle and Nerve, 2021, 63, 108-113.	1.0	2
20	Determinants of therapeutic lag in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1838-1851.	1.4	3
21	An Australian State-Based Cohort Study of Autoimmune Encephalitis Cases Detailing Clinical Presentation, Investigation Results, and Response to Therapy. Frontiers in Neurology, 2021, 12, 607773.	1.1	15
22	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. Genome Biology, 2021, 22, 90.	3.8	49
23	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology, 2021, 96, .	1.5	41
24	Post-COVID Opsoclonus Myoclonus Syndrome: A Case Report From Pakistan. Frontiers in Neurology, 2021, 12, 672524.	1.1	14
25	The effectiveness of natalizumab vs fingolimodâ€"A comparison of international registry studies. Multiple Sclerosis and Related Disorders, 2021, 53, 103012.	0.9	8
26	Venous creatinine as a biomarker for loss of fatâ€free mass and disease progression in patients with amyotrophic lateral sclerosis. European Journal of Neurology, 2021, 28, 3615-3625.	1.7	10
27	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. CNS Drugs, 2021, 35, 1217-1232.	2.7	8
28	MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 722237.	1.1	8
29	Cytokines as a marker of central nervous system autoantibody associated epilepsy. Epilepsy Research, 2021, 176, 106708.	0.8	3
30	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology, 2021, 96, e783-e797.	1.5	54
31	Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis. Medicine (United States), 2021, 100, e27421.	0.4	6
32	Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study). JMIR Research Protocols, 2021, 10, e24969.	0.5	4
33	Response to treatment in NMOSD: the Australasian experience. Multiple Sclerosis and Related Disorders, 2021, 58, 103408.	0.9	0
34	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	9.4	223
35	Risk of secondary progressive multiple sclerosis: A longitudinal study. Multiple Sclerosis Journal, 2020, 26, 79-90.	1.4	52
36	Cylindrical spirals in two families: Clinical and genetic investigations. Neuromuscular Disorders, 2020, 30, 151-158.	0.3	7

#	Article	IF	Citations
37	Plasma from some patients with amyotrophic lateral sclerosis exhibits elevated formaldehyde levels. Journal of the Neurological Sciences, 2020, 409, 116589.	0.3	8
38	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2020, 38, 101868.	0.9	29
39	Sexual Dimorphism in the Immune System. , 2020, , 419-428.		2
40	Treatment response score to glatiramer acetate or interferon beta-1a. Neurology, 2020, 96, 10.1212/WNL.0000000000010991.	1.5	6
41	The spectrum of language impairments in amyotrophic lateral sclerosis. Cortex, 2020, 132, 349-360.	1.1	9
42	Reduced IÎºB-Î± Protein Levels in Peripheral Blood Cells of Patients with Multiple Sclerosisâ€"A Possible Cause of Constitutive NF-ÎºB Activation. Journal of Clinical Medicine, 2020, 9, 2534.	1.0	2
43	Serial MRI studies over 12â€‰months using manual and atlas-based region of interest in patients with amyotrophic lateral sclerosis. BMC Medical Imaging, 2020, 20, 90.	1.4	2
44	Genome-wide Meta-analysis Finds the ACSL5-ZDHHC6 Locus Is Associated with ALS and Links Weight Loss to the Disease Genetics. Cell Reports, 2020, 33, 108323.	2.9	41
45	Altered skeletal muscle glucose-fatty acid flux in amyotrophic lateral sclerosis. Brain Communications, 2020, 2, fcaa154.	1.5	32
46	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain, 2020, 143, 2742-2756.	3.7	24
47	Early clinical markers of aggressive multiple sclerosis. Brain, 2020, 143, 1400-1413.	3.7	32
48	The Peripheral Immune System and Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2020, 11, 279.	1.1	57
49	Mutations in heat shock protein beta-1 (HSPB1) are associated with a range of clinical phenotypes related to different patterns of motor neuron dysfunction: A case series. Journal of the Neurological Sciences, 2020, 413, 116809.	0.3	14
50	What do we know about the variability in survival of patients with amyotrophic lateral sclerosis?. Expert Review of Neurotherapeutics, 2020, 20, 921-941.	1.4	10
51	Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years. Multiple Sclerosis and Related Disorders, 2020, 43, 102146.	0.9	23
52	Levels of clusterin, CD5L, ficolin-3, and gelsolin in ALS patients and controls. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 631-634.	1.1	9
53	A missense mutation in the MLKL brace region promotes lethal neonatal inflammation and hematopoietic dysfunction. Nature Communications, 2020, 11, 3150.	5.8	75
54	Human brain neurons express a novel splice variant of excitatory amino acid transporter 5 (hEAAT5v). Journal of Comparative Neurology, 2020, 528, 3134-3142.	0.9	1

#	Article	IF	Citations
55	Significant out-of-sample classification from methylation profile scoring for amyotrophic lateral sclerosis. Npj Genomic Medicine, 2020, 5, 10.	1.7	25
56	Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation. Frontiers in Neurology, 2020, 11, 537.	1.1	27
57	Takotsubo Cardiomyopathy in Myasthenic Crisis. Journal of Clinical Neuromuscular Disease, 2020, 21, 244-245.	0.3	1
58	Progression and survival of patients with motor neuron disease relative to their fecal microbiota. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 549-562.	1.1	27
59	Monocytes and neutrophils are associated with clinical features in amyotrophic lateral sclerosis. Brain Communications, 2020, 2, fcaa013.	1.5	26
60	The clinical profile of NMOSD in Australia and New Zealand. Journal of Neurology, 2020, 267, 1431-1443.	1.8	17
61	The potential interplay between energy metabolism and innate complement activation in amyotrophic lateral sclerosis. FASEB Journal, 2020, 34, 7225-7233.	0.2	8
62	Elevated Levels of Homocysteinesulfinic Acid in the Plasma of Patients with Amyotrophic Lateral Sclerosis: A Potential Source of Excitotoxicity?. Neurodegenerative Diseases, 2020, 20, 200-206.	0.8	2
63	Women who contributed to past research in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1440-1443.	1.4	1
64	Loss of appetite is associated with a loss of weight and fat mass in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 497-505.	1.1	38
65	Gut microbiota in ALS: possible role in pathogenesis?. Expert Review of Neurotherapeutics, 2019, 19, 785-805.	1.4	30
66	Interaction of neurotransmitters and neurochemicals with lymphocytes. Journal of Neuroimmunology, 2019, 332, 99-111.	1.1	53
67	Tract integrity in amyotrophic lateral sclerosis: 6â€“month evaluation using MR diffusion tensor imaging. BMC Medical Imaging, 2019, 19, 19.	1.4	7
68	134â€…Cladribine: a multicentre long-term efficacy biomarker australian study (CLOBAS). Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A43.3-A43.	0.9	0
69	002â€…Therapeutic lag in relapsing multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A1.2-A1.	0.9	1
70	047â€…Acute lumbosacral plexopathy after blood loss in a patient with bilateral common iliac artery occlusion. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A16.1-A16.	0.9	0
71	Patient with ALS with a novel TBK1 mutation, widespread brain involvement, behaviour changes and metabolic dysfunction. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 952-954.	0.9	6
72	Cumulative influence of parity-related genomic changes in multiple sclerosis. Journal of Neuroimmunology, 2019, 328, 38-49.	1.1	9

#	Article	IF	Citations
73	Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 955-956.	0.9	17
74	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 458-468.	0.9	71
75	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Multiple Sclerosis and Related Disorders, 2019, 28, 235-243.	0.9	35
76	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 175.	3.8	336
77	Increased constitutive activation of NF-Î²B p65 (RelA) in peripheral blood cells of patients with progressive multiple sclerosis. Journal of Neuroimmunology, 2018, 320, 111-116.	1.1	13
78	Mass spectrometry analysis of plasma from amyotrophic lateral sclerosis and control subjects. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 362-376.	1.1	38
79	Hypermetabolism in ALS is associated with greater functional decline and shorter survival. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1016-1023.	0.9	177
80	Cladribine versus fingolimod, natalizumab and interferon Î² for multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1617-1626.	1.4	36
81	A combined tract-based spatial statistics and voxel-based morphometry study of the first MRI scan after diagnosis of amyotrophic lateral sclerosis with subgroup analysis. Journal of Neuroradiology, 2018, 45, 41-48.	0.6	23
82	The Short and Long-Term Effects of Pregnancy on Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Journal of Clinical Medicine, 2018, 7, 494.	1.0	13
83	044â€…Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A18.2-A19.	0.9	0
84	Genome-wide association study in Guillain-BarrÃ© syndrome. Journal of Neuroimmunology, 2018, 323, 109-114.	1.1	13
85	Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 266-276.	1.4	30
86	Screening for cognitive and behavioural impairment in amyotrophic lateral sclerosis: Frequency of abnormality and effect on survival. Journal of the Neurological Sciences, 2017, 376, 16-23.	0.3	42
87	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, The, 2017, 16, 271-281.	4.9	134
88	Anthropometric measures are not accurate predictors of fat mass in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 486-491.	1.1	19
89	Incidence and prevalence of NMOSD in Australia and New Zealand. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 632-638.	0.9	108
90	Extra-motor abnormalities in amyotrophic lateral sclerosis: another layer of heterogeneity. Expert Review of Neurotherapeutics, 2017, 17, 561-577.	1.4	24

#	Article	IF	Citations
91	Hypermetabolism in motor neurone disease is associated with a greater functional decline but not weight loss. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, e1.13-e1.	0.9	0
92	The risk of overestimating fatness in motor neurone disease: longitudinal assessments of body composition. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, e1.32-e1.	0.9	0
93	Comparison of faecal microbe diversity between motor neurone disease (mnd) and control participants. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, e1.83-e1.	0.9	0
94	Cross-ethnic meta-analysis identifies association of the GPX3-TNIP1 locus with amyotrophic lateral sclerosis. Nature Communications, 2017, 8, 611.	5.8	93
95	Whole exome sequencing and <scp>DNA</scp> methylation analysis in a clinical amyotrophic lateral sclerosis cohort. Molecular Genetics & Genomic Medicine, 2017, 5, 418-428.	0.6	14
96	Gelsolin, clusterin and cd5l are the potential plasma biomarkers of amyotrophic lateral sclerosis with and without cognitive impairment. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, e1.31-e1.	0.9	0
97	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology, 2017, 89, 1050-1059.	1.5	38
98	timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, e1.11-e1.	0.9	0
99	Screening for cognitive and behavioural impairment in patients with amyotrophic lateral sclerosis: frequency of abnormality and effect on survival. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, e1.25-e1.	0.9	0
100	Assessment of Motor Units in Neuromuscular Disease. Neurotherapeutics, 2017, 14, 69-77.	2.1	24
101	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain, 2017, 140, 2426-2443.	3.7	94
102	Predictions of resting energy expenditure in amyotrophic lateral sclerosis are greatly impacted by reductions in fat free mass. Cogent Medicine, 2017, 4, 1343000.	0.7	7
103	Exploring targets and therapies for amyotrophic lateral sclerosis: current insights into dietary interventions. Degenerative Neurological and Neuromuscular Disease, 2017, Volume 7, 95-108.	0.7	19
104	1127â€...Pregnancy outcomes in alemtuzumab trials and registry design. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A3.1-A3.	0.9	0
105	A Case Series of Patients With Autoimmune Myasthenia Gravis in Association With Invasive Thymoma. Journal of Clinical Neuromuscular Disease, 2016, 17, 129-134.	0.3	1
106	Defining secondary progressive multiple sclerosis. Brain, 2016, 139, 2395-2405.	3.7	281
107	Altered Metabolic Homeostasis in Amyotrophic Lateral Sclerosis: Mechanisms of Energy Imbalance and Contribution to Disease Progression. Neurodegenerative Diseases, 2016, 16, 382-397.	0.8	49
108	PREGNANCY OUTCOMES IN ALEMTUZUMAB-TREATED PATIENTS WITH RRMS. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.63-e1.	0.9	4

#	Article	IF	Citations
109	Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. BMJ Open, 2016, 6, e012054.	0.8	48
110	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1343-1349.	0.9	63
111	Predictors of longâ€term disability accrual in relapseâ€onset multiple sclerosis. Annals of Neurology, 2016, 80, 89-100.	2.8	158
112	When does ALS start? A novel SOD-1 p.Gly142Arg mutation causing motor neurone disease with prominent premorbid cramps and spasms. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1031-1032.	0.9	3
113	Interleukin 6 promoter 174 G/C polymorphisms in acute ischemic stroke: G allele is protective but not associated with IL-6 levels or stroke outcome. Journal of Neuroimmunology, 2016, 293, 22-27.	1.1	8
114	Targeted assessment of lower motor neuron burden is associated with survival in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 184-190.	1.1	34
115	Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0164625.	1.1	85
116	A new era in the treatment of multiple sclerosis. Medical Journal of Australia, 2015, 203, 139-141.	0.8	10
117	Clinical features and impact of myasthenia gravis disease in Australian patients. Journal of Clinical Neuroscience, 2015, 22, 1164-1169.	0.8	77
118	Serial measurements of phosphorylated neurofilament-heavy in the serum of subjects with amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2015, 353, 122-129.	0.3	47
119	Female infertility and multiple sclerosis: Is this an issue?. Multiple Sclerosis Journal, 2015, 21, 5-7.	1.4	22
120	Switch to natalizumab versus fingolimod in active relapsingâ€“remitting multiple sclerosis. Annals of Neurology, 2015, 77, 425-435.	2.8	143
121	High Caloric Diets in Amyotrophic Lateral Sclerois. , 2015, , 355-361.		0
122	Circulating brain derived neurotrophic factor (BDNF) and frequency of BDNF positive T cells in peripheral blood in human ischemic stroke: Effect on outcome. Journal of Neuroimmunology, 2015, 286, 42-47.	1.1	47
123	Venous thromboembolism in amyotrophic lateral sclerosis: Should we consider routine prophylactic anticoagulation?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 280-281.	1.1	4
124	Pactrims Invited Lecture / Ordinary Submission. Multiple Sclerosis Journal, 2015, 21, 799-838.	1.4	3
125	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. JAMA Neurology, 2015, 72, 405.	4.5	100
126	The frequencies of Killer immunoglobulin-like receptors and their HLA ligands in chronic inflammatory demyelinating polyradiculoneuropathy are similar to those in Guillian Barre syndrome but differ from those of controls, suggesting a role for NK cells in pathogenesis. Journal of Neuroimmunology, 2015, 285, 53-56.	1.1	7

#	Article	IF	Citations
127	Altered expression of metabolic proteins and adipokines in patients with amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2015, 357, 22-27.	0.3	70
128	Exposing asymmetric gray matter vulnerability in amyotrophic lateral sclerosis. NeuroImage: Clinical, 2015, 7, 782-787.	1.4	24
129	Multiparity in women with multiple sclerosis causes less long-term disability: No. Multiple Sclerosis Journal, 2014, 20, 1435-1436.	1.4	5
130	Correlation of Adrenomedullin gene expression in peripheral blood leukocytes with severity of ischemic stroke. International Journal of Neuroscience, 2014, 124, 271-280.	0.8	10
131	Study of motor asymmetry in ALS indicates an effect of limb dominance on onset and spread of weakness, and an important role for upper motor neurons. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 481-487.	1.1	48
132	Increased expression of the hypoxiaâ€related genes in peripheral blood leukocytes of human subjects with acute ischemic stroke. Clinical and Experimental Neuroimmunology, 2014, 5, 216-226.	0.5	2
133	Killer immunoglobulin-like receptor and their HLA ligands in Guillainâ€“BarrÃ© Syndrome. Journal of Neuroimmunology, 2014, 267, 92-96.	1.1	24
134	Sexual Dimorphism in the Immune System. , 2014, , 319-328.		3
135	Gender differences in autoimmune disease. Frontiers in Neuroendocrinology, 2014, 35, 347-369.	2.5	695
136	Marginal reversible jump Markov chain Monte Carlo with application to motor unit number estimation. Computational Statistics and Data Analysis, 2014, 72, 128-146.	0.7	6
137	Genetics of Guillainâ€BarrÃ© syndrome (<scp>GBS</scp>) and chronic inflammatory demyelinating polyradiculoneuropathy (<scp>CIDP</scp>): current knowledge and future directions. Journal of the Peripheral Nervous System, 2014, 19, 88-103.	1.4	55
138	Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood. Journal of Neuroimmunology, 2014, 276, 213-218.	1.1	60
139	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies. Journal of Clinical Neuroscience, 2014, 21, 1835-1846.	0.8	15
140	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy. Journal of Clinical Neuroscience, 2014, 21, 1847-1856.	0.8	22
141	Characterization of genetic variants in the NFKBIA promoter region in multiple sclerosis. Journal of Neuroimmunology, 2014, 275, 53-54.	1.1	0
142	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations. Journal of Clinical Neuroscience, 2014, 21, 1857-1865.	0.8	19
143	Body mass index and dietary intervention: Implications for prognosis of amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2014, 340, 5-12.	0.3	46
144	Clinical features of patients with Guillainâ€BarrÃ© syndrome at seven hospitals on the East Coast of Australia. Journal of the Peripheral Nervous System, 2013, 18, 316-320.	1.4	24

#	Article	IF	Citations
145	Susac syndrome and multifocal motor neuropathy first manifesting in pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2013, 53, 314-317.	0.4	19
146	The relationship between limb dominance, disease lateralization and spread of weakness in amyotrophic lateral sclerosis (ALS). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 150-151.	1.1	11
147	Female reproductive issues in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 392-402.	1.4	51
148	Growth Hormone Secretion Is Correlated With Neuromuscular Innervation Rather Than Motor Neuron Number in Early-Symptomatic Male Amyotrophic Lateral Sclerosis Mice. Endocrinology, 2013, 154, 4695-4706.	1.4	25
149	A developmental perspective on bulbar involvement in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 638-639.	1.1	5
150	A Simple and Reliable Immunohistochemical Method for Colocalization of 2 Antigens in the Same Cells of Paraffin-embedded Tissues. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 471-477.	0.6	1
151	Levels of interleukinÂ33 and soluble suppression of tumorigenicityÂ2 in acute ischemic stroke. Clinical and Experimental Neuroimmunology, 2013, 4, 339-347.	0.5	1
152	Interleukin-6 Gene Promoter-572 C Allele May Play a Role in Rate of Disease Progression in Multiple Sclerosis. International Journal of Molecular Sciences, 2012, 13, 13667-13679.	1.8	17
153	Impairments to the GH-IGF-I Axis in hSOD1G93A Mice Give Insight into Possible Mechanisms of GH Dysregulation in Patients with Amyotrophic Lateral Sclerosis. Endocrinology, 2012, 153, 3735-3746.	1.4	21
154	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet, The, 2012, 380, 1819-1828.	6.3	1,041
155	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet, The, 2012, 380, 1829-1839.	6.3	1,040
156	Structural hemispheric asymmetries in the human precentral gyrus hand representation. Neuroscience, 2012, 210, 211-221.	1.1	28
157	The relationship between Bayesian motor unit number estimation and histological measurements of motor neurons in wild-type and SOD1G93A mice. Clinical Neurophysiology, 2012, 123, 2080-2091.	0.7	34
158	Quantitative studies of lower motor neuron degeneration in amyotrophic lateral sclerosis: Evidence for exponential decay of motor unit numbers and greatest rate of loss at the site of onset. Clinical Neurophysiology, 2012, 123, 2092-2098.	0.7	24
159	Use of Bayesian MUNE to show differing rate of loss of motor units in subgroups of ALS. Clinical Neurophysiology, 2012, 123, 2446-2453.	0.7	16
160	Direct evidence of intra- and interhemispheric corticomotor network degeneration in amyotrophic lateral sclerosis: An automated MRI structural connectivity study. NeuroImage, 2012, 59, 2661-2669.	2.1	61
161	Reduced levels of interleukin 33 and increased levels of soluble ST2 in subjects with amyotrophic lateral sclerosis. Journal of Neuroimmunology, 2012, 249, 93-95.	1.1	35
162	Gene Expression in the Spinal Cord in Female Lewis Rats with Experimental Autoimmune Encephalomyelitis Induced with Myelin Basic Protein. PLoS ONE, 2012, 7, e48555.	1.1	12

#	Article	IF	Citations
163	The role of epigenetic mechanisms and processes in autoimmune disorders. Biologics: Targets and Therapy, 2012, 6, 307.	3.0	51
164	Frequency and function of regulatory T cells after ischaemic stroke in humans. Journal of Neuroimmunology, 2012, 243, 89-94.	1.1	70
165	Prolonged elevation of cytokine levels after human acute ischaemic stroke with evidence of individual variability. Journal of Neuroimmunology, 2012, 246, 78-84.	1.1	22
166	Levels of phosphorylated axonal neurofilament subunit H (pNfH) are increased in acute ischemic stroke. Journal of the Neurological Sciences, 2011, 304, 117-121.	0.3	58
167	The Role of Immune and Inflammatory Mechanisms in ALS. Current Molecular Medicine, 2011, 11, 246-254.	0.6	188
168	Atypical clinical presentations of the A3243G mutation, usually associated with MELAS. Internal Medicine Journal, 2011, 41, 199-202.	0.5	10
169	Role of gender in multiple sclerosis: Clinical effects and potential molecular mechanisms. Journal of Neuroimmunology, 2011, 234, 7-18.	1.1	119
170	Guillain-BarrÃ© Syndrome: Modern Theories of Etiology. Current Allergy and Asthma Reports, 2011, 11, 197-204.	2.4	50
171	Use and monitoring of low dose rituximab in myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 659-663.	0.9	83
172	Effects of gender in amyotrophic lateral sclerosis. Gender Medicine, 2010, 7, 557-570.	1.4	268
173	Effects of prolonged repetitive stimulation of median, ulnar and peroneal nerves. Muscle and Nerve, 2010, 41, 785-793.	1.0	13
174	The effect of ageing on human lymphocyte subsets: comparison of males and females. Immunity and Ageing, 2010, 7, 4.	1.8	133
175	Biomarkers of disease in a case of familial lower motor neuron ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 486-489.	2.3	10
176	T cells from patients with Guillain-BarrÃ© syndrome produce interferon-gamma in response to stimulation with the ganglioside GM1. Journal of Clinical Neuroscience, 2010, 17, 537-538.	0.8	8
177	63. Immune response in acute ischaemic stroke. Journal of Clinical Neuroscience, 2010, 17, 1629.	0.8	0
178	66. Clinical characteristics of Aquaporin 4 auto-antibody positive patients â€“ A case series. Journal of Clinical Neuroscience, 2010, 17, 1629-1630.	0.8	0
179	80. Clinical features of patients with demyelinating neuropathy associated with Anti-MAG antibody. Journal of Clinical Neuroscience, 2010, 17, 1633.	0.8	0
180	Use of respiratory function tests to predict survival in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 194-202.	2.3	77

#	Article	IF	Citations
181	Bladder dysfunction in multiple sclerosis. Expert Review of Neurotherapeutics, 2009, 9, 331-340.	1.4	32
182	Biological basis for motor unit number estimation through Bayesian statistical analysis of the stimulusâ€“response curve. Supplements To Clinical Neurophysiology, 2009, 60, 39-45.	2.1	4
183	Bayesian analysis of the stimulusâ€“response curve. Supplements To Clinical Neurophysiology, 2009, 60, 47-56.	2.1	0
184	Results of Bayesian statistical analysis in normal and ALS subjects. Supplements To Clinical Neurophysiology, 2009, 60, 57-63.	2.1	5
185	Sexual Dimorphism in Autoimmune Disease. Current Molecular Medicine, 2009, 9, 1058-1079.	0.6	144
186	Immune activation in the peripheral blood of patients with acute ischemic stroke. Journal of Neuroimmunology, 2009, 206, 112-117.	1.1	98
187	CMAP decrement in ALS. Muscle and Nerve, 2009, 39, 555-556.	1.0	21
188	Recombinant EPF/chaperonin 10 promotes the survival of O4-positive pro-oligodendrocytes prepared from neonatal rat brain. Cell Stress and Chaperones, 2008, 13, 467-474.	1.2	9
189	Autoantibodyâ€mediated bowel and bladder dysfunction in a patient with chronic, nondiabetic neuropathy. Muscle and Nerve, 2008, 37, 537-543.	1.0	1
190	Immune and Inflammatory Responses to Stroke: Good Or Bad?. International Journal of Stroke, 2008, 3, 254-265.	2.9	67
191	Increased levels of activated T-cells and reduced levels of CD4/CD25+ cells in peripheral blood of Guillain-BarrÃ© syndrome patients compared to controls. Journal of Clinical Neuroscience, 2008, 15, 1031-1035.	0.8	41
192	Bayesian statistical MUNE method. Muscle and Nerve, 2007, 36, 206-213.	1.0	49
193	Motor unit number estimation using reversible jump Markov chain Monte Carlo methods. Journal of the Royal Statistical Society Series C: Applied Statistics, 2007, 56, 235-269.	0.5	18
194	Postural orthostatic tachycardia syndrome: an underrecognized disorder. Internal Medicine Journal, 2007, 37, 529-535.	0.5	11
195	Motor Unit Number Estimation-A Bayesian Approach. Biometrics, 2006, 62, 1235-1250.	0.8	61
196	Studies of HLA associations in male and female patients with Guillainâ€“BarrÃ© syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Journal of Neuroimmunology, 2006, 180, 172-177.	1.1	42
197	The stimulusâ€“response curve and motor unit variability in normal subjects and subjects with amyotrophic lateral sclerosis. Muscle and Nerve, 2006, 34, 34-43.	1.0	51
198	Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 419-422.	0.9	39

#	Article	IF	Citations
199	Riluzole: a glimmer of hope in the treatment of motor neurone disease. Medical Journal of Australia, 2005, 183, 164-165.	0.8	0
200	T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1431-1439.	0.9	76
201	Increased circulating T cell reactivity to GM1 ganglioside in patients with Guillainâ€“BarrÃ© syndrome. Journal of Clinical Neuroscience, 2005, 12, 409-415.	0.8	27
202	Effect of gender on T-cell proliferative responses to myelin proteolipid protein antigens in patients with multiple sclerosis and controls. Journal of Autoimmunity, 2004, 22, 345-352.	3.0	31
203	Early pregnancy factor treatment suppresses the inflammatory response and adhesion molecule expression in the spinal cord of SJL/J mice with experimental autoimmune encephalomyelitis and the delayed-type hypersensitivity reaction to trinitrochlorobenzene in normal BALB/c mice. Journal of the Neurological Sciences, 2003, 212, 37-46.	0.3	46
204	Early pregnancy factor suppresses the infiltration of lymphocytes and macrophages in the spinal cord of rats during experimental autoimmune encephalomyelitis but has no effect on apoptosis. Journal of the Neurological Sciences, 2003, 214, 27-36.	0.3	32
205	A protective effect of early pregnancy factor on experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein. Journal of the Neurological Sciences, 2003, 216, 33-41.	0.3	32
206	Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. Journal of Clinical Neuroscience, 2003, 10, 63-66.	0.8	57
207	Gender issues in multiple sclerosis. Expert Review of Neurotherapeutics, 2003, 3, 649-660.	1.4	2
208	Cyclosporin A treatment modulates cytokine mRNA expression by inflammatory cells extracted from the spinal cord of rats with experimental autoimmune encephalomyelitis induced by inoculation with myelin basic protein. Journal of the Neurological Sciences, 2001, 187, 7-16.	0.3	11
209	The Effects of Pregnancy on Myelin Basic Protein-induced Experimental Autoimmune Encephalomyelitis in Lewis Rats: Suppression of Clinical Disease, Modulation of Cytokine Expression in the Spinal Cord Inflammatory Infiltrate and Suppression of Lymphocyte P. American Journal of Reproductive Immunology, 2001, 46, 405-412.	1.2	8
210	Surges of Increased T Cell Reactivity to an Encephalitogenic Region of Myelin Proteolipid Protein Occur More Often in Patients with Multiple Sclerosis Than in Healthy Subjects. Journal of Immunology, 2000, 165, 5322-5331.	0.4	62
211	Chronic inflammatory demyelinating polyradiculoneuropathy and severe peripheral oedema: a renal explanation. Journal of Clinical Neuroscience, 2000, 7, 148-149.	0.8	8
212	Results of testing for anti-GM1 antibodies. Journal of Clinical Neuroscience, 2000, 7, 209-212.	0.8	14
213	Early pregnancy factor suppresses experimental autoimmune encephalomyelitis induced in Lewis rats with myelin basic protein and in SJL/J mice with myelin proteolipid protein peptide 139-151. Journal of the Neurological Sciences, 2000, 182, 5-15.	0.3	33
214	Effects of cyclosporin A treatment on clinical course and inflammatory cell apoptosis in experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein. Journal of Neuroimmunology, 1999, 97, 60-69.	1.1	21
215	Early pregnancy factor, a chaperonin 10 homologue, aids in recovery of rats from experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 1998, 90, 58.	1.1	0
216	T cell apoptosis, but not microglial adoptosis, is mediated by the FAS pathway in the central nervous system in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 1998, 90, 62.	1.1	0

#	Article	IF	Citations
217	The frequency of circulating T cells reactive to PLP184-209 increases prior to MS relapse and development of new MR1 lesions. Journal of Neuroimmunology, 1998, 90, 76.	1.1	0
218	The roles of Fas, Fas ligand and Bcl-2 in T cell apoptosis in the central nervous system in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 1998, 82, 47-55.	1.1	63
219	Cytokine expression by inflammatory cells obtained from the spinal cords of Lewis rats with experimental autoimmune encephalomyelitis induced by inoculation with myelin basic protein and adjuvants. Journal of Neuroimmunology, 1998, 88, 30-38.	1.1	25
220	Microglia are more susceptible than macrophages to apoptosis in the central nervous system in experimental autoimmune encephalomyelitis through a mechanism not involving Fas (CD95). International Immunology, 1998, 10, 935-941.	1.8	61
221	Increased Apoptosis of T Lymphocytes and Macrophages in the Central and Peripheral Nervous Systems of Lewis Rats with Experimental Autoimmune Encephalomyelitis Treated with Dexamethasone. Journal of Neuropathology and Experimental Neurology, 1997, 56, 58-69.	0.9	59
222	Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain, 1997, 120, 1447-1460.	3.7	71
223	Apoptosis of VÎ²8.2+ T lymphocytes in the spinal cord during recovery from experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein. Journal of the Neurological Sciences, 1996, 139, 1-6.	0.3	27
224	A study of human T-cell lines generated from multiple sclerosis patients and controls by stimulation with peptides of myelin basic protein. Journal of Neuroimmunology, 1996, 70, 65-74.	1.1	18
225	Corticosteroid treatment of experimental autoimmune encephalomyelitis in the Lewis rat results in loss of VÎ²8.2+ and myelin basic protein-reactive cells from the spinal cord, with increased total T-cell apoptosis but reduced apoptosis of VÎ²8.2+ cells. Journal of Neuroimmunology, 1996, 70, 93-101.	1.1	44
226	Apoptosis of V beta 8.2+ T lymphocytes in the spinal cord during recovery from experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein. Journal of the Neurological Sciences, 1996, 139, 1-6.	0.3	10
227	Conduction abnormalities are restricted to the central nervous system in experimental autoimmune encephalomyelitis induced by inoculation with proteolipid protein but not with myelin basic protein. Brain, 1995, 118, 1073-1073.	3.7	0
228	Restoration of conduction in the spinal roots correlates with clinical recovery from experimental autoimmune encephalomyelitis. Muscle and Nerve, 1995, 18, 1093-1100.	1.0	7
229	The proximal peripheral nervous system is a major site of demyelination in experimental autoimmune encephalomyelitis induced in the Lewis rat by a myelin basic protein-specific T cell clone. Acta Neuropathologica, 1995, 89, 527-531.	3.9	26
230	Antigen-specific down-regulation of myelin basic protein-reactive T cells during spontaneous recovery from experimental autoimmune encephalomyelitis: further evidence of apoptotic deletion of autoreactive T cells in the central nervous system. International Immunology, 1995, 7, 967-973.	1.8	62
231	The Guillainâ€“BarrÃ© syndrome and acute dysautonomia. , 1995, , 202-228.		0
232	An introduction to neuroimmunology. , 1995, , 14-25.		5
233	Experimental autoimmune encephalomyelitis. , 1995, , 26-88.		12
234	Acute disseminated encephalomyelitis. , 1995, , 155-165.		5

#	Article	IF	Citations
235	The stiff-man syndrome. , 1995, , 166-176.		2
236	Neurological complications of connective tissue diseases and vasculitis. , 1995, , 345-360.		1
237	Autoimmune diseases of the neuromuscular junction and other disorders of the motor unit. , 1995, , 257-303.		0
238	Paraneoplastic neurological disorders. , 1995, , 327-344.		0
239	Inflammatory myopathies and experimental autoimmune myositis. , 1995, , 304-326.		0
240	Chronic immune-mediated neuropathies. , 1995, , 229-256.		0
241	Antigen recognition and selfâ€“non-self discrimination. , 1995, , 1-13.		0
242	Experimental autoimmune neuritis. , 1995, , 177-201.		0
243	The proximal peripheral nervous system is a major site of demyelination in experimental autoimmune encephalomyelitis induced in the Lewis rat by a myelin basic protein-specific T cell clone. Acta Neuropathologica, 1995, 89, 527-531.	3.9	0
244	Apoptotic elimination of VÎ²8.2+ cells from the central nervous system during recovery from experimental autoimmune encephalomyelitis induced by the passive transfer of VÎ²8.2+ encephalitogenic T cells. European Journal of Immunology, 1994, 24, 2609-2617.	1.6	117
245	Clinical and histological findings in proteolipid protein-induced experimental autoimmune encephalomyelitis (EAE) in the lewis rat. Distribution of demyelination differs from that in EAE induced by other antigens. Journal of the Neurological Sciences, 1994, 123, 154-161.	0.3	33
246	Inflammatory cells, microglia and MHC class II antigen-positive cells in the spinal cord of Lewis rats with acute and chronic relapsing experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 1994, 51, 153-167.	1.1	41
247	T cells and microglia in chronic relapsing EAE: Evidence that T cells are CD45RCâ^' and that microglia proliferate. Journal of Neuroimmunology, 1994, 54, 181.	1.1	0
248	Demyelination and nerve conduction abnormalities are restricted to the CNS in PLP-EAE but not in MBP-EAE. Journal of Neuroimmunology, 1994, 54, 189.	1.1	0
249	Antigen-specific downregulation of the T cell response associated with T cell apoptosis in the CNS during EAE. Journal of Neuroimmunology, 1994, 54, 200.	1.1	0
250	Macrophage Apoptosis in the Central Nervous System in Experimental Autoimmune Encephalomyelitis. Journal of Autoimmunity, 1994, 7, 145-152.	3.0	74
251	Conduction abnormalities are restricted to the central nervous system in experimental autoimmune encephalomyelitis induced by inoculation with proteolipid protein but not with myelin basic protein. Brain, 1994, 117, 975-986.	3.7	17
252	Failure to detect measles virus sequences in lymphocytes of patients with multiple sclerosis. Australian and New Zealand Journal of Medicine, 1993, 23, 55-55.	0.5	2

#	Article	IF	Citations
253	Spasticity and white matter abnormalities in adult phenylketonuria.. Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 359-361.	0.9	41
254	Vestibular and ventilatory dysfunction in sensory and autonomic neuropathy associated with primary Sjorgren's syndrome.. Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 1211-1212.	0.9	10
255	Apoptosis of Î±Î² T lymphocytes in the nervous system in experimental autoimmune encephalomyelitis: Its possible implications for recovery and acquired tolerance. Journal of Autoimmunity, 1992, 5, 401-410.	3.0	114
256	Expression of CD45RC and Ia antigen in the spinal cord in acute experimental allergic encephalomyelitis: An immunocytochemical and flow cytometric study. Journal of the Neurological Sciences, 1992, 113, 177-186.	0.3	30
257	Neuropathological findings in chronic relapsing experimental allergic neuritis induced in the Lewis rat by inoculation with intradural root myelin and treatment with low dose cyclosporin A. Neuropathology and Applied Neurobiology, 1992, 18, 171-187.	1.8	11
258	Focal conduction block in the dorsal root ganglion in experimental allergic neuritis. Annals of Neurology, 1992, 31, 27-33.	2.8	4
259	Anti-ganglioside antibodies in peripheral neuropathy. Clinical and Experimental Neurology, 1992, 29, 182-8.	0.0	3
260	Apoptosis in the nervous system in experimental allergic encephalomyelitis. Journal of the Neurological Sciences, 1991, 104, 81-87.	0.3	234
261	Cronkhiteâ€Canada syndrome associated with peripheral neuropathy. Australian and New Zealand Journal of Medicine, 1991, 21, 379-379.	0.5	6
262	Monoclonal immunoglobulin bands in the cerebrospinal fluid. Australian and New Zealand Journal of Medicine, 1991, 21, 227-229.	0.5	18
263	Sensorimotor peripheral neuropathy in rheumatoid arthritis. Clinical and Experimental Neurology, 1991, 28, 146-53.	0.0	3
264	Lack of neurological abnormalities in Lewis rats with experimental chronic serum sickness. Clinical and Experimental Neurology, 1991, 28, 139-45.	0.0	4
265	Familial occurrence of multiple sclerosis with thyroid disease and systemic lupus erythematosus. Journal of the Neurological Sciences, 1990, 97, 163-171.	0.3	42
266	The effects of prophylactic cyclosporin A on experimental allergic neuritis (EAN) in the Lewis rat. Induction of relapsing EAN using low dose cyclosporin A. Journal of Neuroimmunology, 1990, 28, 131-140.	1.1	45
267	Progressive encephalomyelitis with rigidity: a case report with magnetic resonance imaging findings.. Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 1429-1431.	0.9	29
268	Absence of antimyelin antibodies and serum demyelinating factors in most patients with chronic inflammatory demyelinating polyradiculoneuropathy. Clinical and Experimental Neurology, 1988, 25, 53-60.	0.0	3
269	PERIPHERAL SENSORIMOTOR AND AUTONOMIC NEUROPATHY ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS. Brain, 1987, 110, 533-549.	3.7	97
270	CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY. Brain, 1987, 110, 1617-1630.	3.7	459

#	Article	IF	Citations
271	Chronic inflammatory demyelinating polyradiculoneuropathy associated with pregnancy. Annals of Neurology, 1987, 21, 102-104.	2.8	64
272	Class II antigen expression and T lymphocyte subsets in chronic inflammatory demyelinating polyneuropathy. Journal of Neuroimmunology, 1986, 13, 123-134.	1.1	111
273	?-1 antitrypsin phenotypes in demyelinating disease: An association between demyelinating disease and the allele PiM3. Annals of Neurology, 1985, 18, 514-516.	2.8	47
274	The peripheral neuropathy of vitamin B12 deficiency. Journal of the Neurological Sciences, 1984, 66, 117-126.	0.3	112
275	Uninfected avian cells contain RNA related to the transforming gene of avian sarcoma viruses. Cell, 1978, 13, 371-379.	13.5	118
276	Use of respiratory function tests to predict survival in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 0, , 1-9.	2.3	3
277	Functional Characterisation of a GWAS Risk Locus Identifies GPX3 as a Lead Candidate Gene in ALS. SSRN Electronic Journal, 0, , .	0.4	0
278	HLA and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 0, , 1-9.	1.1	2